Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(66.7%)
Phase 1
2(33.3%)
6Total
N/A(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06279689Not ApplicableRecruiting

Echography Study_Anthropometric Measurements

Role: lead

NCT05967013Not ApplicableCompleted

Evaluation by Magnetic Resonance Imaging of Intramuscular Injections Performance in Thigh With 2 Configurations of the Needle-free Injector ZENEO®.

Role: lead

NCT05026567Phase 1Completed

Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®

Role: lead

NCT03103334Phase 1Completed

A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.

Role: lead

NCT03225638Not ApplicableUnknown

Performance Evaluation by Magnetic Resonance Imaging (MRI) of Intramuscular Thigh Injections With 3 Configurations of Needle-free Injector (ZENEO®)

Role: lead

NCT03044301Not ApplicableCompleted

Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)

Role: lead

All 6 trials loaded